Article Versions Notes

Schlichtig K, Cuba L, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell PJ, Mackensen A, Dörje F, Fromm MF, et al. New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial. Journal of Clinical Medicine. 2022; 11(15):4558. https://doi.org/10.3390/jcm11154558

Schlichtig, Katja, Lisa Cuba, Pauline Dürr, Laura Bellut, Norbert Meidenbauer, Frank Kunath, Peter J. Goebell, Andreas Mackensen, Frank Dörje, Martin F. Fromm, and et al. 2022. "New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial" Journal of Clinical Medicine 11, no. 15: 4558. https://doi.org/10.3390/jcm11154558

Schlichtig, K., Cuba, L., Dürr, P., Bellut, L., Meidenbauer, N., Kunath, F., Goebell, P. J., Mackensen, A., Dörje, F., Fromm, M. F., & Wullich, B. (2022). New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial. Journal of Clinical Medicine, 11(15), 4558. https://doi.org/10.3390/jcm11154558